Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well erlotinib works in treating patients with stage I,
stage II, or stage IIIA non-small cell lung cancer. Erlotinib may stop the growth of tumor
cells by blocking the enzymes necessary for their growth. Giving erlotinib before surgery may
shrink the tumor so that it can be removed.